UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
At 50, focusing on the right investments is essential. Learn which options can help you achieve your retirement goals.
19,777 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Global markets surged after President Trump hinted at de-escalation in Iran, easing oil risks and boosting equities. ...
BioNTech’s stock is under pressure as investors react to weak guidance and leadership pivots. This deep dive breaks d...
SDNY prosecutors seek a new trial for Tornado Cash co-founder Roman Storm in October 2026, even as U.S. agencies ackn...
Earnings calls reveal the health of specialized housing providers. This guide breaks down how to interpret target hos...
Oil volatility could create a rare buy-on-dip window for memory names. Jim Cramer says Western Digital and Micron may...
Reno has overtaken Las Vegas as the top destination for California homebuyers seeking affordability, driven by supply...
Stocks with dividends are drawing buyers as growth slows. HDV and SPYD command big flows, yet risk signals suggest on...
Defense markets are shifting as missiles that changed balance drive bigger budgets and stronger stock moves. This rep...
This guide shares a real-world route to achieve from zero $8,000/month cash flow while working a full-time job. Learn...
If you want amplified daily moves, SPXL and TQQQ offer two very different paths. This guide breaks down costs, risk, ...
A 2,000-year GDP chart is fueling debate about long-run shifts in economic power. Dalio’s pattern idea is driving fre...